Lifecore Biomedical, Inc. (LFCR)
| Market Cap | 207.80M -18.4% |
| Revenue (ttm) | 129.46M +0.8% |
| Net Income | -34.50M |
| EPS | -0.93 |
| Shares Out | 37.51M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 229,682 |
| Open | 5.58 |
| Previous Close | 5.52 |
| Day's Range | 5.48 - 5.65 |
| 52-Week Range | 3.63 - 8.98 |
| Beta | 1.07 |
| Analysts | Buy |
| Price Target | 6.83 (+23.29%) |
| Earnings Date | Aug 6, 2026 |
About LFCR
Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization that serves customers in the United States, Belgium, the Netherlands, and internationally. It provides services in the development, manufacture, aseptic fill, and finish of formulations and highly viscous sterile injectable pharmaceutical drug or medical device products in syringes, vials, and cartridges in various modalities. The company also manufactures and sells pharmaceutical-grade hyaluronic acid in bulk... [Read more]
Financial Performance
In 2025, Lifecore Biomedical's revenue was $129.46 million, an increase of 0.46% compared to the previous year's $128.87 million. Losses were -$34.50 million, -22.22% less than in 2025.
Financial StatementsAnalyst Summary
According to 5 analysts, the average rating for LFCR stock is "Buy." The 12-month stock price target is $6.83, which is an increase of 23.29% from the latest price.
News
Lifecore Biomedical Signs New Agreement with Global Pharmaceutical Company
--Agreement Supports Tech Transfer and Commercial Manufacturing of Currently Marketed Neurology Product-- --Seventh Addition to Lifecore's Late-Stage Pipeline in Seven Months-- CHASKA, Minn., June 15,...
Lifecore Biomedical Transcript: AGM 2026
The meeting covered director elections, auditor ratification, executive compensation, and a new stock incentive plan, all of which were approved by shareholders. No questions were raised, and final voting results will be filed with the SEC.
Lifecore Biomedical Signs Agreement with New Biopharmaceutical Customer
-- Agreement Calls for Tech Transfer in Preparation for Potential Commercial Manufacturing of Injectable Ophthalmic Product -- -- Sixth Addition to Late-Stage Pipeline in Seven Months -- CHASKA, Minn....
Lifecore Biomedical to Participate in William Blair 46th Annual Growth Stock Conference
CHASKA, Minn., May 21, 2026 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated injectables contract development and manufacturing organization (“CDMO”), toda...
Lifecore Biomedical to Participate at CDMO Live Europe
CHASKA, Minn., May 12, 2026 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated injectables contract development and manufacturing organization (“CDMO”), to...
Lifecore Biomedical Earnings Call Transcript: Q1 2026
Q1 2026 saw a 34% revenue decline year-over-year, but cost reductions and new business wins support reaffirmed 2026 guidance. Strong pipeline growth, especially in prefilled syringes, and positive cash flow position the company for a stronger second half.
Lifecore Biomedical Earnings release: Q1 2026
Lifecore Biomedical released its Q1 2026 earnings on May 6, 2026, summarizing the period's financial results.
Lifecore Biomedical Quarterly report: Q3 2026
Lifecore Biomedical has published its Q3 2026 quarterly earnings report on May 6, 2026.
Lifecore Biomedical Reports Financial Results for the First Quarter Ended March 31, 2026, and Provides Corporate Update
-- Reaffirms 2026 Guidance -- -- Signed Three New Commercial Site Transfer Programs in First Quarter 2026 -- -- Cost Containment Initiatives Continue to Drive Down Expenses -- Conference Call Today at...
Lifecore Biomedical to Report Financial Results for the First Quarter Ended March 31, 2026, on May 6, 2026
CHASKA, Minn., April 29, 2026 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated injectables contract development and manufacturing organization (“CDMO”), ...
Lifecore Biomedical Proxy statement: Proxy filing
Lifecore Biomedical filed a proxy statement on April 24, 2026, providing details for shareholder voting and corporate governance matters.
Lifecore Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
CHASKA, Minn., April 22, 2026 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”) a fully integrated injectables contract development and manufacturing organization (“CDMO”), tod...
Lifecore Biomedical to Participate at 12th Annual American Biomanufacturing Summit
CHASKA, Minn., April 08, 2026 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated injectables contract development and manufacturing organization (“CDMO”), to...
Lifecore Biomedical Signs Two New Agreements with Existing U.S. Biopharmaceutical Customer
-- Site Transfer Agreement for the Manufacture of Commercially Marketed Product -- -- Second Agreement Supports the Expansion of Product Commercially Manufactured at Lifecore to a New Delivery System ...
Lifecore Biomedical Signs Commercial Site Transfer Agreement with Leading Medical Aesthetics Company
-- Agreement for the Commercial Manufacture of Established, Approved Aesthetic Product -- -- Third Commercial Site Transfer Agreement Win in Five Months -- -- Program Expected to Generate Commercial R...
Lifecore Biomedical Transcript: 2026 KeyBanc Capital Markets Healthcare Forum
The company has transformed into a pure-play life sciences CDMO, focusing on sterile injectables and hyaluronic acid fermentation. With reinforced mid-term revenue and margin targets, a robust late-stage pipeline, and new tech transfer agreements, growth is driven by reshoring trends and expanding partnerships. Capacity utilization and operational efficiency are set to improve through 2029.
Lifecore Biomedical Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses
SAN DIEGO, March 16, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential claims on behalf of investors of Lifecore Biomedical, Inc. The investigation focuses on Lifecore Biomedica...
Lifecore Biomedical Transcript: Transition period
Revenue and EBITDA margins grew strongly in 2025, driven by pipeline expansion, operational efficiencies, and new business wins. 2026 guidance anticipates stable revenue and margin progression, with significant growth expected from 2027 as major customer demand and late-stage pipeline launches accelerate.
Lifecore Biomedical Earnings release: Transition period
Lifecore Biomedical released its earnings on March 16, 2026, summarizing the period's financial results.
Lifecore Biomedical Slides: Transition period
Lifecore Biomedical has posted slides in relation to its latest quarterly earnings report, which was published on March 16, 2026.
Lifecore Biomedical Reports Financial Results for the Fourth Quarter and Transition Period Ended December 31, 2025, and Provides Corporate Update
-- Recorded Fourth Quarter Revenues of $35.7 Million and Transition Period Revenues of $75.5 Million -- -- Multiple New Programs Signed in Fourth Quarter 2025 Including Two Commercial Site Transfer P...
Lifecore Biomedical Slides: Investor presentation
Lifecore Biomedical has posted slides in relation to its latest quarterly earnings report, which was published on March 16, 2026.
Lifecore Biomedical to Participate in 6th Annual KeyBanc Capital Markets Healthcare Virtual Forum
CHASKA, Minn., March 10, 2026 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated injectables contract development and manufacturing organization (“CDMO”), to...
Lifecore Biomedical to Report Financial Results for the Fourth Quarter and Transition Period Ended December 31, 2025, on March 16, 2026
CHASKA, Minn., March 09, 2026 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated injectables contract development and manufacturing organization (“CDMO”), to...
Lifecore Biomedical Signs New Agreement with Indomo to Support Innovative Drug/Device Combination Acne Treatment
Indomo Developing Fast-Acting, At-Home Treatment for Inflammatory Acne Lesions to be Administered with the ClearPen ™ , its Proprietary Intradermal Self-Injection Device Lifecore to Manufacture Drug B...